AzTrials
AzTrials

MentholNCT07745049

Acute Effects of Menthol Gargle and Buccal Film on Anaerobic Capacity and Respiratory Parameters in Male Volleyball Players

A study testing Menthol gargle and Menthol buccal film in people with Menthol, run by Vedat Cinar at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Menthol activates the transient receptor potential melastatin 8 (TRPM8) channel and can alter thermal and respiratory perception without producing an actual reduction in body or tissue temperature. Read more about this study

Who is it for?
Ages 18 years and older, men onlyHealthy volunteers can take part
Conditions the study is for
Menthol
What is being tested?
Menthol gargle and Menthol buccal film
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
16 participants
Where
1 siteTurkey (Türkiye)
Study dates
25 Nov 2025to 5 Jan 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult
  • Healthy male volleyball player
  • Training regularly
  • No chronic disease
  • No active injury
  • Non-smoker
  • No alcohol consumption
  • No regular use of medications, dietary supplements or performance-enhancing substances
  • No known hypersensitivity to menthol
  • Provision of written informed consent
  • Allergy to menthol or to any other component used in the interventions
  • Pharmacological treatment within the preceding three months
  • History of chronic disease or serious injury
  • Any health condition that could affect test performance

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Fırat University

    Fırat, Merkez, 23100

Other trials in Turkey (Türkiye)

About this study

Menthol activates the transient receptor potential melastatin 8 (TRPM8) channel and can alter thermal and respiratory perception without producing an actual reduction in body or tissue temperature. Evidence on whether oral menthol improves short-duration maximal (anaerobic) performance is limited and inconsistent, and almost all existing exercise studies have delivered menthol as a mouth rinse, solution, gel or topical preparation. A menthol-containing buccal film represents a distinct route of oral administration, because it adheres to the buccal mucosa and may alter the residence time and release profile of menthol in the oral cavity. No controlled exercise study has compared a menthol-containing buccal film with menthol mouth-rinsing and a placebo condition in athletes.

This single-blind, randomized, three-condition crossover trial compares the acute effects of a placebo (water control), menthol mouth-rinsing, and a menthol-containing buccal film on anaerobic performance in male volleyball players. The primary outcome is anaerobic performance measured with the 30-second Wingate Anaerobic Power Test. Secondary (exploratory) outcomes are respiratory function assessed by spirometry, post-exercise blood lactate concentration, and post-exercise plasma hypoxia-inducible factor-1 alpha (HIF-1alpha) concentration.

Read more

Each participant completes all three conditions in a randomized order, separated by 72-hour washout periods. Both active conditions deliver a standardized total of 10 mg of L-menthol.

All testing sessions are conducted at the same time of day, under similar environmental conditions, and by the same researcher.

Read the detailed description

BACKGROUND AND RATIONALE Volleyball is an intermittent team sport characterized by repeated jumps, sudden accelerations, short-duration maximal or near-maximal movements, and limited recovery intervals. Rapid lower-extremity power production and the ability to sustain it across repeated high-intensity actions are therefore central to volleyball performance.

Menthol is a natural monoterpene that produces a cooling sensation by activating the TRPM8 channel in thermosensory neurons. This sensory response does not correspond to an actual reduction in skin or core temperature, which suggests that any acute effect of oral menthol on exercise may operate through perceptual and behavioral rather than thermal mechanisms.

Findings on strength, power and high-intensity exercise are more limited and inconsistent than those on thermal perception, and recent meta-analytic evidence does not support menthol mouth-rinsing as a consistent ergogenic strategy. Whether menthol affects anaerobic performance under thermoneutral conditions during short-duration maximal exercise remains unclear.

In most exercise studies menthol has been delivered as a mouth rinse, beverage, gel or topical preparation. A buccal film is a distinct oral dosage form: it adheres to the buccal mucosa and, depending on formulation, can alter the residence time and release profile of the incorporated compound in the oral cavity. In pharmaceutical research menthol has generally been studied as a permeation enhancer or excipient rather than as the primary active compound. The dissolution rate, release profile, mucosal absorption and sensory exposure produced by a menthol-containing buccal film cannot be inferred from mouth-rinsing studies. The buccal film is therefore investigated here as an experimental route of administration with no established physiological or ergogenic superiority, not as a presumed enhancement.

HIF-1alpha regulates genes associated with glycolytic metabolism, oxygen homeostasis and angiogenesis, and exercise has been shown to affect HIF-1alpha protein levels and HIF-1-related signaling in human skeletal muscle. At the cell-culture level, menthol-induced TRPM8 activation has been reported to stabilize HIF-1alpha protein through a calcium- dependent, oxygen-independent mechanism. HIF-1alpha is therefore included as an exploratory biomarker of the biological response to high-intensity exercise under the three conditions.

OBJECTIVES Primary objective: to compare the acute effects of placebo (water control), menthol mouth-rinsing, and a menthol-containing buccal film on anaerobic performance assessed by the Wingate Anaerobic Power Test in male volleyball players. Secondary (exploratory) objectives: to compare the effects of the three conditions on respiratory function, post-exercise blood lactate concentration, and post-exercise plasma HIF-1alpha concentration.

HYPOTHESIS There will be significant differences among the placebo, menthol mouth-rinsing, and menthol-containing buccal-film conditions in anaerobic performance, respiratory function, blood lactate concentration, and plasma HIF-1alpha concentration.

DESIGN Single-blind, randomized, three-condition crossover trial. Each participant completes all three conditions. The order of conditions is determined by randomization. A 72-hour washout period separates conditions to minimize carryover effects.

SAMPLE SIZE An a priori power analysis was conducted using G*Power 3.1.9.7 for a repeated-measures within-subjects ANOVA with one group and three repeated measurements, assuming an effect size f = 0.35, alpha = 0.05, power (1-beta) = 0.80, correlation among repeated measures r = 0.50, and nonsphericity correction epsilon = 1.00. The required minimum sample size was 15 participants (achieved power 0.81). Nineteen volunteers were assessed for eligibility to allow for attrition.

INTERVENTIONS Placebo (water control): a total of 40 mL of tap water given as two separate 20 mL volumes; each volume is rinsed around the mouth for 30 seconds and expectorated without swallowing (total rinsing time 60 seconds). Menthol gargle (MG): a total of 40 mL of solution containing 10 mg L-menthol (0.025% w/v), given as two separate 20 mL volumes; each volume is rinsed for 30 seconds and expectorated without swallowing (total rinsing time 60 seconds). The concentration was selected based on the range of L-menthol concentrations used in exercise studies. Menthol buccal film (MBF): a film containing a total of 10 mg L-menthol placed on the buccal mucosa within the oral cavity. Total L-menthol content is standardized at 10 mg across both active conditions.

PROCEDURES PER SESSION

  1. Body weight is remeasured to set the Wingate resistance load.
  2. Standardized 15-minute warm-up (10 minutes light running, 5 minutes stretching).
  3. Administration of the assigned condition (P, MG or MBF).
  4. Spirometry in the seated position, with nose clip and disposable mouthpiece, performed according to the 2019 ATS/ERS spirometry standardization statement. At least three acceptable maneuvers are obtained and FEV1/FVC repeatability is verified. The highest FVC and FEV1 from acceptable maneuvers are used.
  5. Approximately one minute after spirometry, the 30-second Wingate Anaerobic Power Test is performed on a mechanically braked Monark 834E cycle ergometer at a resistance of 7.5% of body weight, with standardized verbal encouragement, participants remaining seated.
  6. Immediately after the Wingate test, a 5 mL venous blood sample is drawn from the antecubital vein into an EDTA tube.

BLOOD SAMPLE HANDLING Tubes are inverted 8-10 times. Within 30 minutes of collection, samples are centrifuged at 1500 x g for 15 minutes at 4 degrees C. Plasma is aliquoted into sterile microtubes without contacting the cellular layer and stored at -80 degrees C until analysis.

BIOCHEMICAL ANALYSES Plasma HIF-1alpha is measured by a commercial human HIF-1alpha sandwich ELISA (Reed Biotech Ltd., Wuhan, China; catalogue no. RE2787H) and expressed as pg/mL. Lactate is measured by a commercial lactic acid assay kit (Reed Biotech Ltd., Wuhan, China; catalogue no. RE10064) and expressed as mmol/L. Samples and standards are analyzed in duplicate; absorbance is read on a BioTek ELx800 microplate reader.

STANDARDIZATION AND CONTROL OF CONFOUNDERS Participants refrain from menthol-containing products for one week before the first condition, and from caffeine, alcohol, menthol-containing products and strenuous exercise for 72 hours before each condition. Dietary intake is recorded for the 72 hours before the first condition and participants are asked to maintain a similar dietary pattern before subsequent conditions. All sessions are conducted at 72-hour intervals, at the same time of day, under similar environmental conditions, and by the same researcher. Ergometer seat and handlebar settings are individualized at the first session and kept unchanged thereafter.

BLINDING Participants are not informed of the study hypothesis or the expected direction of effects.

The researcher preparing and administering the conditions is aware of the allocation.

Because of the differences between routes of administration and the perceptible cooling sensation produced by menthol, complete participant blinding is not achievable; blinding is therefore implemented by restricting participants' access to information about the hypothesis and expected effects.

STATISTICAL ANALYSIS Continuous variables are summarized as mean and standard deviation. Normality is assessed with the Shapiro-Wilk test. Differences among conditions are examined with one-way repeated-measures ANOVA with condition as a three-level within-subject factor. Sphericity is assessed with Mauchly's test. For variables with a significant omnibus condition effect, pairwise comparisons are performed with Bonferroni correction. Effect size is reported as partial eta squared. All tests are two-tailed with alpha set at 0.05.

Conditions
Menthol
Being tested
Placebo (water control), Menthol gargle, Menthol buccal film
Keywords
Menthol, anaerobic performance, respiratory parameters.

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Placebo (water control)Other

    40 mL of tap water administered as two 20 mL volumes; each rinsed for 30 seconds and expectorated without swallowing.

  • Menthol gargleOther

    40 mL of aqueous solution containing 10 mg L-menthol (0.025% w/v), administered as two 20 mL volumes; each rinsed for 30 seconds and expectorated without swallowing.

  • Menthol buccal filmOther

    Buccal film containing 10 mg L-menthol, applied to the buccal mucosa.

Study groups in NCT07745049
Study groupRoleWhat they receive
Placebo (water control)Placebo comparatorParticipants received a total of 40 mL of tap water as two separate 20 mL volumes. Each volume was rinsed around the mouth for 30 seconds and expectorated without swallowing (total rinsing time 60 seconds). Spirometry, the Wingate Anaerobic Power Test and post-exercise venous blood sampling followed.
Receives: Other: Placebo (water control)
Menthol gargle (MG)ExperimentalParticipants received a total of 40 mL of solution containing 10 mg L-menthol (0.025% w/v) as two separate 20 mL volumes. Each volume was rinsed around the mouth for 30 seconds and expectorated without swallowing (total rinsing time 60 seconds). Spirometry, the Wingate Anaerobic Power Test and post-exercise venous blood sampling followed.
Receives: Other: Menthol gargle
Menthol buccal film (MBF)ExperimentalA buccal film containing a total of 10 mg L-menthol was placed on the buccal mucosa within the oral cavity. Spirometry, the Wingate Anaerobic Power Test and post-exercise venous blood sampling followed.
Receives: Other: Menthol buccal film

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Peak power during the Wingate Anaerobic Power Test

    Peak power output (W) during a 30-second Wingate Anaerobic Power Test performed on a mechanically braked Monark 834E cycle ergometer at a resistance of 7.5% of body weight. Calculated with Monark Anaerobic Test Software Version 3.

    Measured: During the 30-second Wingate Anaerobic Power Test performed after each intervention, at each of the three study visits separated by 72 hours.

  2. Mean power during the Wingate Anaerobic Power Test

    Mean power output (W) across the 30-second Wingate Anaerobic Power Test performed on a mechanically braked Monark 834E cycle ergometer at a resistance of 7.5% of body weight. Calculated with Monark Anaerobic Test Software Version 3.

    Measured: During the 30-second Wingate Anaerobic Power Test performed after each intervention, at each of the three study visits separated by 72 hours.

  3. Relative peak power during the Wingate Anaerobic Power Test

    Peak power output normalized to body weight (W/kg) during a 30-second Wingate Anaerobic Power Test. Body weight was remeasured on each testing day.

    Measured: During the 30-second Wingate Anaerobic Power Test performed after each intervention, at each of the three study visits separated by 72 hours.

  4. Post-exercise blood lactate concentration

    Lactate concentration (mmol/L) in plasma obtained from a 5 mL venous blood sample drawn from the antecubital vein into an EDTA tube immediately after the Wingate test, centrifuged at 1500 x g for 15 minutes at 4 degrees C within 30 minutes of collection, and measured with a commercial lactic acid assay kit (Reed Biotech Ltd., catalogue no. RE10064) in duplicate.

    Measured: Immediately after completion of the Wingate Anaerobic Power Test, at each of the three study visits separated by 72 hours.

Secondary outcomes (4)
  1. Forced vital capacity (FVC)

    Forced vital capacity (L) measured by spirometry in the seated position with a nose clip and disposable mouthpiece, according to the 2019 ATS/ERS spirometry standardization statement. At least three acceptable maneuvers were obtained; the highest acceptable value was used.

    Measured: After each intervention and immediately before the Wingate Anaerobic Power Test, at each of the three study visits separated by 72 hours.

  2. Forced expiratory volume in 1 second (FEV1)

    FEV1 (L) measured by spirometry according to the 2019 ATS/ERS standardization statement. At least three acceptable maneuvers were obtained and FEV1 repeatability was verified; the highest acceptable value was used.

    Measured: After each intervention and immediately before the Wingate Anaerobic Power Test, at each of the three study visits separated by 72 hours.

  3. Peak expiratory flow (PEF)

    Peak expiratory flow (L/s) measured by spirometry according to the 2019 ATS/ERS standardization statement.

    Measured: After each intervention and immediately before the Wingate Anaerobic Power Test, at each of the three study visits separated by 72 hours.

  4. Post-exercise plasma HIF-1alpha concentration

    Plasma hypoxia-inducible factor-1 alpha concentration (pg/mL) measured by a commercial human HIF-1alpha sandwich ELISA (Reed Biotech Ltd., catalogue no. RE2787H) in duplicate, from a 5 mL venous EDTA blood sample drawn immediately after the Wingate test and processed within 30 minutes. Exploratory outcome.

    Measured: Immediately after completion of the Wingate Anaerobic Power Test, at each of the three study visits separated by 72 hours.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Aug 2026
  2. Study start25 Nov 2025
  3. Primary completion2 Jan 2026
  4. Study completion5 Jan 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Crossover
Model description
Each participant completed all three conditions (placebo, menthol gargle, menthol buccal film) in a randomized order, with a 72-hour washout period between conditions.
Masking
Single blind
Who is masked
Participant
Enrolment
16 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07745049
Sponsor's protocol ID
2024/06-42
Status last verified
Jul 2026
First submitted
17 Jul 2026
Last updated
4 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data underlying the reported results (Wingate peak power, mean power, relative peak power; FVC, FEV1, PEF; plasma lactate; plasma HIF-1alpha) will be made available.

Questions about this trial

What is this clinical trial studying?

A study testing Menthol gargle and Menthol buccal film in people with Menthol, run by Vedat Cinar at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Peak power during the Wingate Anaerobic Power Test (time frame: During the 30-second Wingate Anaerobic Power Test performed after each intervention, at each of the three study visits separated by 72 hours.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in